.png){kind=icon}
返回
Cancer therapy optimization based on multiple model adaptive control
.png){kind=icon}
PRE
AI
DOI：10.1016/j.bspc.2018.09.016.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
During the last years several clinical decision support systems have been developed, some of which clearly improved the results obtained with standard clinical practice. However, this kind of decision computing process has not been quite explored in cancer treatment. In this work a control system that designs an optimal therapy based on adaptive control methods, aiming to allow the eradication of a metastatic renal cell carcinoma as quickly and efficiently as possible, and with lower associated toxicity, is developed. In order to do so, a new mathematical model describing the growth of this kind of tumor is developed, taking into account the effects of two of the most promising therapies: anti-angiogenesis and immunotherapy. Additionally, models describing pharmacodynamical aspects of the organism are also included. The therapy is designed through multiple model adaptive control. Together with a system of selection and aggregation of key classes of models, it allows to deal with the uncertainty associated with the patient, namely his intra- and inter-patient variability. The simulation results show that the approach proposed presents robustness in terms of stability and performance. The reference tracking errors for the simulations are around 3%, which allows a tumor eradication in less than a year and a half with mild and moderate toxicity levels. Therefore, the tool developed allows to contribute with new perspectives in the creation of decision support systems for cancer therapy, thus enhancing the medical choices. (C) 2018 Elsevier Ltd. All rights reserved.
Keyword:
Cancer therapy design
Tumor growth model
Anti-angiogenesis
Immunotherapy
Multiple model adaptive control
Model clustering
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
4.9
论文数:
1.0W
被引数:
2.4W
机构
引用论文
A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity.png)
BMC CANCER
OAAI
BMC CANCERIF3.4
OAAI分享收藏分享收藏Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma
PREAI
分享收藏
查看更多内容